Sunday, April 28, 2019

Victoza® demonstrated superiority in reducing blood sugar vs placebo in children and adolescents with type 2 diabetes

BALTIMORE, April 28, 2019 /PRNewswire/ -- Novo Nordisk today announced the results from the ELLIPSE trial which examined efficacy and safety and demonstrated superiority of Victoza® (liraglutide) injection 1.8 mg vs placebo in reducing blood sugar in children and adolescents aged 10-17...



from PR Newswire: https://prn.to/2PD4JY2

No comments:

Post a Comment